MARKET

CMRX

CMRX

Chimerix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.990
+0.220
+12.43%
After Hours: 1.960 -0.03 -1.51% 19:58 05/27 EDT
OPEN
1.800
PREV CLOSE
1.770
HIGH
2.070
LOW
1.730
VOLUME
7.27M
TURNOVER
0
52 WEEK HIGH
9.29
52 WEEK LOW
1.570
MARKET CAP
174.00M
P/E (TTM)
-1.7155
1D
5D
1M
3M
1Y
5Y
Co-Diagnostics extends gains on monkeypox test development
The shares of Co-Diagnostics (NASDAQ:CODX) are trading higher for the third straight session on Friday in solidarity with makers of monkeypox vaccines and therapeutics after molecular diagnostics company announced its
Seekingalpha · 6h ago
EXPLAINER-What vaccines, treatments do we have to combat monkeypox?
reuters.com · 2d ago
Monkeypox cases rise prompting vaccinations in U.S., Britain, and Germany
Countries from the U.S. to Germany are planning to offer monkeypox vaccinations as the rare viral disease continues to spread outside Central and West Africa, where it is usually detected.
Seekingalpha · 3d ago
PLG, ZTEK and BBAI among mid-day movers
Gainers: Better Therapeutics (BTTX) +26%. America's Car-Mart (CRMT) +25%. GeoVax Labs (GOVX) +17%. Platinum Group Metals (PLG) +17%. Zentek (ZTEK) +16%. China Liberal Education Holdings (CLEU) +13%. Charge Enterprises (CRGE)
Seekingalpha · 3d ago
50 Stocks Moving In Tuesday's Mid-Day Session
 Gainers CynergisTek, Inc. (NYSE: CTEK) jumped 100% to $1.18 after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7 million.
Benzinga · 3d ago
Triangle market caps keep tanking – Duke economist explains the volatility
The public markets plunge continues, with a Raleigh technology firm’s market cap tanking 82 percent year-over-year – just one of many firms feeling the pressure. A review of market cap data conducted by the Business Journals shows virtually all Triangle p...
American City Business Journals · 3d ago
Moderna enters monkeypox vaccine development
The COVID-19 vaccine maker Moderna (NASDAQ:MRNA) announces that the company is currently investigating potential monkeypox vaccines at a pre-clinical stage. The Cambridge, Massachusetts-based biotech made the statement at a time when the
Seekingalpha · 3d ago
Clusters of monkeypox cases are driving up stock prices for some companies
Concern about monkeypox has sent shares of several vaccine and drug companies soaring.
marketwatch.com · 4d ago
More
No Data
Learn about the latest financial forecast of CMRX. Analyze the recent business situations of Chimerix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CMRX stock price target is 7.67 with a high estimate of 11.00 and a low estimate of 5.00.
High11.00
Average7.67
Low5.00
Current 1.990
EPS
Actual
Estimate
-0.36-0.27-0.18-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 164
Institutional Holdings: 62.70M
% Owned: 71.70%
Shares Outstanding: 87.44M
TypeInstitutionsShares
Increased
35
2.32M
New
17
2.66M
Decreased
44
2.84M
Sold Out
13
780.50K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Martha Demski
President/Chief Executive Officer/Director
Michael Sherman
Chief Financial Officer
Michael Andriole
Other
Allen Melemed
Independent Director
Catherine Gilliss
Independent Director
Patrick Machado
Independent Director
Robert Meyer
Independent Director
Fred Middleton
Independent Director
Pratik Multani
Independent Director
Victoria Vakiener
No Data
No Data
About CMRX
Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The Company's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.

Webull offers kinds of Chimerix Inc stock information, including NASDAQ:CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMRX stock methods without spending real money on the virtual paper trading platform.